Literature DB >> 17145609

Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia.

Ola Landgren1, Joshua S Rapkin, Lene Mellemkjaer, Gloria Gridley, Lynn R Goldin, Eric A Engels.   

Abstract

Encounter with infectious antigens has been proposed to initiate the cascade of events associated with progression from premalignancy (monoclonal gammopathy of undetermined significance, MGUS) to multiple myeloma (MM). We conducted a population-based case-control study to evaluate risk of developing MM associated with a personal history of various respiratory tracts infections occurring >1 year prior to MM. Inpatient (1977-1997) and outpatient (1994-1997) diagnoses were obtained for all MM patients (n=4,476) diagnosed in Denmark (1977-1997) and 16,727 matched controls. A personal history of pneumonia was associated with a 1.6-fold (95%CI 1.3-2.0) increased risk of MM; the elevated risk was restricted to 1-4.99 years prior to the diagnosis of MM (OR=1.7,95%CI 1.3-2.2). Individuals with two and three or more previous episodes of pneumonia had a 1.7-fold (95%CI 1.0-3.0; p=0.05) and a 1.5-fold (95%CI 0.6-3.9) elevated MM risk, respectively. Pneumonia could be a trigger to the development of MM or a manifestation of immune disturbances in late-stage MGUS.

Entities:  

Mesh:

Year:  2006        PMID: 17145609

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

Review 1.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 2.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

3.  Medication use and multiple myeloma risk in Los Angeles County.

Authors:  Daniel S Nuyujukian; Jenna Voutsinas; Leslie Bernstein; Sophia S Wang
Journal:  Cancer Causes Control       Date:  2014-07-01       Impact factor: 2.506

Review 4.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

5.  Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.

Authors:  Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

6.  Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.

Authors:  Sigurdur Y Kristinsson; Jill Koshiol; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  J Natl Cancer Inst       Date:  2010-02-24       Impact factor: 13.506

7.  Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

Review 8.  Autoimmunity and lymphomagenesis.

Authors:  Lynn R Goldin; Ola Landgren
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

9.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

10.  Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Ola Landgren; Lesley A Anderson
Journal:  Int J Cancer       Date:  2013-10-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.